Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs), including anti-PD-1 therapy, have limited efficacy in patients with microsatellite stable (MSS) colorectal cancer (CRC). Interleukin 17A (IL-17A) activity leads to a protumor microenvironment, dependent on its ability to induce the production of infla...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Immunother Cancer
Glavni autori: Liu, Chao, Liu, Ruiqi, Wang, Bojun, Lian, Jie, Yao, Yang, Sun, Haoxiu, Zhang, Chunhui, Fang, Lin, Guan, Xin, Shi, Jiaqi, Han, Shuling, Zhan, Fei, Luo, Shengnan, Yao, Yuanfei, Zheng, Tongsen, Zhang, Yanqiao
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2021
Teme:
Basic Tumor Immunology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7813395/
https://ncbi.nlm.nih.gov/pubmed/33462141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001895
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items